Papaverine safety during pregnancy: Insights from a large population-based cohort of pregnancies
Related Experiment Video
Updated: May 29, 2025
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
Yael Levi1, Tal Michael1, Saar Dor1
1Department of Epidemiology, Biostatistics, and Community Health Sciences, School of Public Health, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Aims:
Papaverine hydrochloride functions as an antispasmodic and vasodilator medication. Data concerning the teratogenic risk of papaverine is currently lacking. The aims of this paper are to examine the association between first-trimester exposure to papaverine and major congenital malformations and the association between third trimester exposure to papaverine and late adverse pregnancy outcomes.
Methods:
We conducted a population-based retrospective cohort study that included pregnant women 15-49 years old insured by 'Clalit Health Services' in southern Israel, who gave birth or had an elective pregnancy termination due to suspected fetal malformation at Soroka Medical Center between 1999 and 2017. Multivariate negative binomial regression models were used to examine the associations between papaverine during the first trimester and major congenital malformations, and between papaverine during the third trimester and late adverse pregnancy outcomes, adjusting for potential confounders.
Results:
The study included a total of 254 333 pregnancies, of which 3604 (1.41%) were exposed to papaverine during the first trimester, and 1253 (0.49%) during the third trimester. No significant associations were found between first-trimester exposure to papaverine and total congenital major malformations or specific malformations according to organ systems in the multivariate analysis (adjusted RR for: total major malformations = 1.021; 95% confidence interval (CI) [0.895-1.165], cardiovascular = 1.073; 95% CI [0.905-1.273], central nervous system = 0.784; 95% CI [0.484-1.271], musculoskeletal = 0.823; 95% CI [0.588-1.153], gastrointestinal = 0.887; 95% CI [0.457-1.718], genitourinary = 1.076; 95% CI [0.805-1.438]). Additionally, we did not detect significant associations between third-trimester exposure to papaverine and late adverse pregnancy outcomes.
Conclusions:
Exposure to papaverine during pregnancy was not associated with adverse pregnancy outcomes in the population studied, compared with non-exposed pregnancies.
More Related Videos
12:17The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo
Published on: August 2, 2017
05:31Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
Related Concept Videos
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:21Factors Affecting Drug Response: Overview
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists